newsfilter
← Latest News
GlobeNewswire·

Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)

WW
  • WW International (Weight Watchers) announced it will offer Novo Nordisk's Ozempic® pill (semaglutide) through its Med+ program & affiliated medical groups.
  • The once-daily oral GLP-1 medication is available for adults with type 2 diabetes to expand the company's portfolio of supported treatments.
  • Many eligible members can access the medication for as little as $25 monthly due to widespread insurance coverage.
  • Weight Watchers provides clinical guidance, insurance navigation, & prior authorization support to help members secure their prescriptions.
  • Eligible members gain access to board-certified clinicians, the Weight Watchers Diabetes Support program, tailored nutrition, coaching, community, & a blood sugar tracker.
  • A study of 136 individuals showed a 0.75% reduction in HbA1c after 6 months on the Weight Watchers diabetes nutrition program.
  • Jon Volkmann, Chief Operations Officer at Weight Watchers, emphasized the importance of comprehensive support including clinical guidance & medication access.
  • Ed Cinca, Senior Vice President at Novo Nordisk, stated the partnership broadens patient access to FDA-approved semaglutide options with clinical backing.
  • The initiative reflects Weight Watchers' strategy to pair trusted brand-name GLP-1 medications with comprehensive real-life support tools.